89796-99-6 Usage
Description
Different sources of media describe the Description of 89796-99-6 differently. You can refer to the following data:
1. Aceclofenac is a non-steroidal anti-inflammatory drug (NSAIDs) that is commonly prescribed for people with painful rheumatic conditions such as rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
The drug should not be given to children, breastfeeding mothers, and people with porphyria. Pregnant women should not also be given aceclofenac as they risk developing patent ductus arteriosus in the neonate.
2. Aceclofenac is a nonsteroidal antiinflammatory agent with analgesic and antipyretic
properties. It is reported to be useful in the treatment of osteoarthritis, rheumatoid
arthritis and pain associated with minor surgical procedures. Compared to ketoprofen
in the treatment of rheumatoid arthritis, aceclofenac is substantially faster acting.
Mechanism of Action
Aceclofenac acts by inhibiting the effect of natural substances known as cyclooxygenase (COX) enzymes. Notably, these enzymes are responsible for making other chemicals in the body, namely prostaglandins. The prostaglandins are normally produced at sites of damages or injury cause inflammation and pain. By blocking the influence of COX enzymes, production of prostaglandins is minimized, meaning that the swelling and pain is eased.
Precautions
Before taking aceclofenac, it is essential to tell the doctor if one has ever had an allergic reaction to any other NSAID, for instance, diclofenac, aspirin, indomethacin, and naproxen; whether one has allergic disorders such as asthma. It is important to alert the doctor if an individual has a heart condition or problem with circulation or blood vessels. Moreover, inform the physician if one has connective tissue disorder, for instance, lupus erythematosus. One should not take the drug if he/she has high blood pressure or has blood-clotting problems.
Chemical Properties
White Crystalline Solid
Originator
Prodes (Prodesfarma) (Spain)
Uses
Different sources of media describe the Uses of 89796-99-6 differently. You can refer to the following data:
1. Labeled Aceclofenac, intended for use as an internal standard for the quantification of Aceclofenac by GC- or LC-mass spectrometry.
2. Aceclofenac is a non-steroidal, anti-inflammatory drug (NSAID) with potent inhibitory activity in several models of inflammation. It is used for the treatment of osteoarthritis and rheumatoid arthritis. It is a Biopharmaceutics classification system class II (BCS class I) drug which has an intermediate half-life of 3-4h and undergoes substantial first pass metabolism. aceclofenac is available either in oral form (tablet) or in topical form (gel).
Definition
ChEBI: Aceclofenac is a monocarboxylic acid that is the carboxymethyl ester of diclofenac. A non-steroidal anti-inflammatory drug related to diclofenac, it is used in the management of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. It has a role as an EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor, a non-steroidal anti-inflammatory drug and a non-narcotic analgesic. It is a monocarboxylic acid, a carboxylic ester, a secondary amino compound, an amino acid and a dichlorobenzene. It derives from a diclofenac.
Brand name
Airtal; Gerbin
Biochem/physiol Actions
Non-steroidal, anti-inflammatory drug (NSAID), with selectivity for COX-2 over COX-1.
Drug interactions
Potentially hazardous interactions with other drugs
ACE inhibitors and angiotensin-II antagonists:
antagonism of hypotensive effect; increased risk of
nephrotoxicity and hyperkalaemia. Analgesics: avoid concomitant use of 2 or more
NSAIDs, including aspirin (increased side effects);
avoid with ketorolac (increased risk of side effects
and haemorrhage).
Antibacterials: possible increased risk of convulsions
with quinolones.
Anticoagulants: effects of coumarins and
phenindione enhanced; possibly increased risk of
bleeding with heparins, dabigatran and edoxaban -
avoid long term use with edoxaban.
Antidepressants: increased risk of bleeding with
SSRIs and venlaflaxine.
Antidiabetic agents: effects of sulphonylureas enhanced.
Antiepileptics: possibly increased phenytoin
concentration.
Antivirals: increased risk of haematological toxicity
with zidovudine; concentration possibly increased by
ritonavir.
Ciclosporin: may potentiate nephrotoxicity
Cytotoxics: reduced excretion of methotrexate;
increased risk of bleeding with erlotinib.
Diuretics: increased risk of nephrotoxicity;
antagonism of diuretic effect, hyperkalaemia with
potassium-sparing diuretics.
Lithium: excretion decreased.
Pentoxifylline: increased risk of bleeding.
Tacrolimus: increased risk of nephrotoxicity.
Metabolism
About two-thirds of a dose is excreted in the urine,
mainly as hydroxymetabolites, the principal one being
4-hydroxyaceclofenac. A small amount is converted to
diclofenac.
Check Digit Verification of cas no
The CAS Registry Mumber 89796-99-6 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 8,9,7,9 and 6 respectively; the second part has 2 digits, 9 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 89796-99:
(7*8)+(6*9)+(5*7)+(4*9)+(3*6)+(2*9)+(1*9)=226
226 % 10 = 6
So 89796-99-6 is a valid CAS Registry Number.
InChI:InChI=1/C16H13Cl2NO4/c17-11-5-3-6-12(18)16(11)19-13-7-2-1-4-10(13)8-15(22)23-9-14(20)21/h1-7,19H,8-9H2,(H,20,21)
89796-99-6Relevant articles and documents
Method for industrially producing aceclofenac
-
Paragraph 0021; 0023-0025; 0027-0029; 0031-0032; 0034-0036, (2020/11/12)
The invention relates to a method for industrially producing aceclofenac. The method comprises the following steps: mixing organic acid, a water removal agent and Lewis acid, fully stirring, and adding aceclofenac tert-butyl ester for acidolysis reaction. The method is mild in reaction condition, high in reaction rate, free of high temperature and high energy consumption, easy and convenient to operate, environmentally friendly, economical and free of participation or generation of major pollutants, most solvents can be recycled, emission of waste solvents is reduced, and therefore the cost isreduced, and the environment is protected.
Preparation method of aceclofenac
-
Paragraph 0031-0034; 0036, (2019/08/30)
The invention discloses a microwave-assisted preparation method of aceclofenac. The method is as follows: under the microwave condition, a compound 2 and a compound 3 are reacted to form a compound 4under the catalysis of KI; and under the microwave condition, a reaction of the compound 4 is carried out in a mixed solvent of formic acid and acetone. According to the method, the acidolysis of aceclofenac tert-butyl ester is carried out in the mixture of formic acid and acetone under the microwave condition, the acidolysis method has high selectivity, the fracture of the ethoxyl group in aceclofenac tert-butyl ester is reduced to the lowest limit, the conversion rate of the acidolysis reaction is high, the diclofenac content in the product is extremely small, the product is easy to refine,and the purity is high.
Synthesis and pharmacological evaluation of mutual prodrugs of aceclofenac with quercetin, vanillin and l-tryptophan as gastrosparing NSAIDS
Rasheed, Arun,Lathika,Raju, Y. Prasanna,Mansoor,Azeem,Balan, Nija
, p. 70 - 82 (2016/01/25)
Synthesis, physicochemical characterization and pharmacological evaluation of mutual prodrugs of aceclofenac with quercetin, vanillin and l-tryptophan have been attempted to develop novel gastrosparing NSAIDs, devoid of ulcerogenic side effects. The structures of synthesized prodrugs were confirmed by IR, 1H NMR, 13C NMR and mass spectroscopy. The hydrolysis kinetics studies were performed in simulated gastric fluid, simulated intestinal fluid and rat fecal matter. Its anti-inflammatory and ulcer index were analyzed along with estimation of biochemical parameters (GWM and Hexosamine), oxidative parameters (LPO, GSH, CAT, and SOD) and protein estimation. The results indicated that the synthesized prodrugs are chemically stable, biolabile and possesses optimum lipophilicity. They also exhibited retention of anti-inflammatory activity with reduced ulcerogenicity. The study showed that the mutual prodrugs are better in action compared to the parent drug and have fewer gastrointestinal side effects.